retatrutide phase 2 trial results Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished 💉 A triple-action once-weekly injection

Resources such as the SAMHSA National Helpline (1-800-662-HELP) can provide treatment referrals, and patients at risk for opioid overdose should be prescribed naloxone

9 Intervention strategies with direct clinical translation potential While drug repurposing based on neurodegenerative disease mechanisms is a core focus of this research, several non-pharmacological or clinically applied interventions also show potential for tinnitus management by modulating these shared pathological pathways

Oral S-Adenosylmethionine in depression: A randomized, double-blind, placebo-controlled trial

For those who have already lost a significant amount of weight or have a lower body fat percentage, a 4mm or 5mm needle might be preferred to avoid hitting the muscle

Read more about us Updated February 10, 2026 Added by Butter